Normal view

Received — 4 January 2026 ⏭ Favourites

Nature Medicine
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial Benjamin L. Musher · Spyridoula Vasileiou · Brandon G. Smaglo · Catherine S. Robertson · Mengfen Wu · Tao Wang · Ayumi Watanabe · Manik Kuvalekar · Yovana Velazquez · Shamika Ketkar · Tamadar Al Doheyan · Penelope G. Papayanni · Aakash Shah · Natalia Lapteva · Bambi J. Grilley · George Van Buren · Premal D. Lulla · Helen E. Heslop · Cliona M. Rooney · Malcolm K. Brenner · Ann M. Leen
Nature Medicine, Published online: 02 January 2026; doi:10.1038/s41591-025-04043-5Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.
2 January 2026 at 08:00

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

By: Benjamin L. Musher · Spyridoula Vasileiou · Brandon G. Smaglo · Catherine S. Robertson · Mengfen Wu · Tao Wang · Ayumi Watanabe · Manik Kuvalekar · Yovana Velazquez · Shamika Ketkar · Tamadar Al Doheyan · Penelope G. Papayanni · Aakash Shah · Natalia Lapteva · Bambi J. Grilley · George Van Buren · Premal D. Lulla · Helen E. Heslop · Cliona M. Rooney · Malcolm K. Brenner · Ann M. Leen

2 January 2026 at 08:00

Nature Medicine, Published online: 02 January 2026; doi:10.1038/s41591-025-04043-5

Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.